# US 2023/0058142 A1 · Liquid pharmaceutical composition comprising cytisine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058142 A1
- Document ID: US20230058142A1
- Status: Published application
- Kind: A1
- Application number: 17/784,243
- Filed: 2020-12-06
- Published: 2023-02-23
- Earliest claimed: 2019-12-10
- Applicants: Adamed Pharma S.A.
- Inventors: Bartlomiej KUBIAK; Joanna RZASA; Mariola ZARZYCKA; Kamil GARBERA
- Web page: https://patentgrep.com/patent/US20230058142A1

## CPC

- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A24B 15/167: in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A24B: MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid harmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.

## Claims

### Claim 1

A liquid pharmaceutical composition comprising:
cytisine;
at least one inorganic pH-regulating agent selected from inorganic acids, inorganic buffers, or inorganic acid salts; and
water;
wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5.

### Claim 2 (depends on 1)

The liquid pharmaceutical composition according to claim 1 wherein the at least one inorganic pH-regulating agent is selected from hydrogen phosphate, dihydrogen phosphate, hydrogen phosphate/dihydrogen phosphate buffer, hydrochloric acid, phosphoric acid, or mixtures thereof.

### Claim 3 (depends on 2)

The liquid pharmaceutical composition according to claim 2 wherein the at least one inorganic pH-regulating agent is selected from hydrogen phosphate, dihydrogen phosphate, or hydrogen phosphate/dihydrogen phosphate buffer.

### Claim 4 (depends on 1)

The liquid pharmaceutical composition according to claim 1 wherein the liquid pharmaceutical composition comprises at least one viscosity agent.

### Claim 5 (depends on 4)

The liquid pharmaceutical composition according to claim 4 wherein the liquid pharmaceutical composition comprises at least one viscosity agent in the amount of 0.01-3% wt.

### Claim 6 (depends on 5)

The liquid pharmaceutical composition according to claim 5 wherein the viscosity agent is sodium hyaluronate or carboxymethylcellulose sodium.

### Claim 7 (depends on 6)

The liquid pharmaceutical composition according to claim 6 wherein the viscosity agent is sodium hyaluronate.

### Claim 8 (depends on 1)

The liquid pharmaceutical composition according to claim 1 wherein the liquid pharmaceutical composition comprises at least one co-solvent.

### Claim 9 (depends on 8)

The liquid pharmaceutical composition according to claim 8 wherein the liquid pharmaceutical composition comprises at least one co-solvent present in the amount of 5-50% wt.

### Claim 10 (depends on 9)

The liquid pharmaceutical composition according to claim 9 wherein the co-solvent is glycerol or propylene glycol, or mixture thereof.

### Claim 11 (depends on 1)

The liquid pharmaceutical composition according to claim 1 wherein the liquid pharmaceutical composition comprises a sweetener selected from a sugar, an artificial sweetener, or mixtures thereof.

### Claim 12 (depends on 11)

The liquid pharmaceutical composition according to claim 11 wherein the sugar or the artificial sweetener is selected from xylitol, mannitol, maltitol, sucrose, acesulfame K, aspartame, or mixtures thereof.

### Claim 13 (depends on 1)

A method for the treatment of addiction comprising administering the liquid pharmaceutical composition according to claim 1 12 1 to a patient in need thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the liquid pharmaceutical composition is administered into the oral cavity of a subject by mist or aerosol.

### Claim 15

A method of treating addiction comprising orally administering an aqueous pharmaceutical composition comprising cytisine to a patient in need thereof.

### Claim 16 (depends on 13)

The method of claim 13, wherein the addiction is nicotine addiction.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nicotine addiction is tobacco smoking addiction.

### Claim 18 (depends on 15)

The method of claim 15, wherein the addiction is nicotine addiction.

### Claim 19 (depends on 18)

The method of claim 18, wherein the nicotine addiction is tobacco smoking addiction.
